Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Peritonitis is one of the most important complications associated with peritoneal dialysis, which can cause deterioration in peritoneal and residual renal function. Among peritonitis, fungal/yeast peritonitis can result in severe peritoneal damage with high mortality and lead patient to encapsulating peritoneal sclerosis (EPS).
Previously, we reported that a rat model of EPS-like fungal peritonitis exhibits severe inflammation and complement activation in the peritoneum. Furthermore, patients with fungal peritonitis also showed the presence of highly activated complement products within the peritoneum. Accordingly, we have conducted various therapeutic experiments based on the hypothesis that controlling the inflammation and complement activation associated with peritonitis, in addition to antimicrobial therapy, could prevent the onset of EPS.
Adrenomedullin (ADM) has been reported to have multiple physiological functions, including anti-inflammatory effects in addition to vasodilation. In peritoneal dialysis, ADM has been detected in the peritoneal effluent and mesothelial cells. However, the role of ADM in the peritoneal cavity remains unclear.
In this study, we examined whether the intraperitoneal injection of ADM exhibit protective role in peritoneal injury in a rat model of fungal/yeast peritonitis.
After administering methylglyoxal (MGO) to SD rats, Zymosan was administered to create a fungal/yeast peritonitis model (MGO/Zy peritonitis). Human ADM (ADM group) or vehicle (control group) was administered intraperitoneally to the rats. Macroscopic and histological findings of peritoneal lesions were compared within each group.
In subsequent experiments, to examine the role of ADM-ADM receptor signaling in MGO/Zy peritonitis, ADM (22-52) was co-injected with ADM as an ADM receptor antagonist.
To evaluate ADM's role in complement system in vitro, rat serum was incubated with zymosan in the presence or absence of ADM.The levels of C3 and C5b-9 were then compared using an ELISA assay.
The macroscopic score, which includes gastrointestinal adhesions, showed lower severity in the ADM group than in the control group. Microscopic examination revealed reduced peritoneal thickness, an accumulation of inflammatory cells and complement deposition.
Administering ADM (22-52) did not fully reverse the effects of peritoneal injury in MGO/Zy peritonitis. ELISA analysis of complement activity on zymosan showed that the addition of ADM reduced C5b-9 levels.
We demonstrated the therapeutic potential of exogenous administration of ADM to inhibit peritoneal injury in fungal/yeast peritonitis through its anti-inflammatory effects, including complement modulatory properties.
